203 related articles for article (PubMed ID: 36923424)
1. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.
Kim YJ; Li W; Zhelev DV; Mellors JW; Dimitrov DS; Baek DS
Front Oncol; 2023; 13():1124039. PubMed ID: 36923424
[TBL] [Abstract][Full Text] [Related]
2. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
[TBL] [Abstract][Full Text] [Related]
3. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
5. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
6. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
[TBL] [Abstract][Full Text] [Related]
7. CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.
Arias Cardenas KC; Enos CW; Spear MR; Austin DE; Almofeez R; Kortchak S; Pincus L; Guo HB; Dolezal S; Pierce JM; Furth E; Gineste C; Kwon Y; Gelber C
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38178674
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
9. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer.
Schettini F; Barbao P; Brasó-Maristany F; Galván P; Martínez D; Paré L; De Placido S; Prat A; Guedan S
ESMO Open; 2021 Jun; 6(3):100102. PubMed ID: 33838601
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer.
Azari F; Kennedy GT; Chang A; Bernstein E; Nadeem B; Pèlegrin A; Cailler F; Sullivan NT; Kucharczuk J; Singhal S
Ann Thorac Surg; 2023 Sep; 116(3):631-641. PubMed ID: 35644263
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
12. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
14. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration.
Zhang X; Han X; Zuo P; Zhang X; Xu H
J Int Med Res; 2020 Sep; 48(9):300060520959478. PubMed ID: 32993395
[TBL] [Abstract][Full Text] [Related]
15. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
16. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
J Nucl Med; 2024 May; ():. PubMed ID: 38782457
[TBL] [Abstract][Full Text] [Related]
17. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
Min J; Long C; Zhang L; Duan J; Fan H; Chu F; Li Z
Bioengineered; 2022 Apr; 13(4):9216-9232. PubMed ID: 35378051
[TBL] [Abstract][Full Text] [Related]
18. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.
Cao YJ; Wang X; Wang Z; Zhao L; Li S; Zhang Z; Wei X; Yun H; Choi SH; Liu Z; Zhao L; Kazane SA
ACS Synth Biol; 2021 May; 10(5):1176-1183. PubMed ID: 33856201
[TBL] [Abstract][Full Text] [Related]
19. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.
Belluomini L; Sposito M; Avancini A; Insolda J; Milella M; Rossi A; Pilotto S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001628
[TBL] [Abstract][Full Text] [Related]
20. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.
Fantini M; David JM; Annunziata CM; Morelli MP; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2020 Apr; 35(3):190-198. PubMed ID: 31928422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
